QQQ   372.49 (+1.64%)
AAPL   169.11 (+1.73%)
MSFT   310.67 (+2.42%)
FB   324.60 (+1.57%)
GOOGL   2,737.33 (+1.30%)
AMZN   3,132.80 (+0.22%)
TSLA   1,033.83 (+3.83%)
NVDA   253.31 (+1.05%)
BABA   133.69 (+4.66%)
NIO   30.51 (+6.57%)
AMD   127.32 (-0.74%)
CGC   8.00 (+4.71%)
MU   89.39 (-0.68%)
GE   101.31 (+0.69%)
T   27.38 (+0.37%)
F   22.49 (+0.18%)
DIS   151.81 (+1.13%)
AMC   19.12 (+4.37%)
PFE   53.96 (+0.78%)
ACB   5.02 (+3.29%)
BA   220.75 (+1.69%)
QQQ   372.49 (+1.64%)
AAPL   169.11 (+1.73%)
MSFT   310.67 (+2.42%)
FB   324.60 (+1.57%)
GOOGL   2,737.33 (+1.30%)
AMZN   3,132.80 (+0.22%)
TSLA   1,033.83 (+3.83%)
NVDA   253.31 (+1.05%)
BABA   133.69 (+4.66%)
NIO   30.51 (+6.57%)
AMD   127.32 (-0.74%)
CGC   8.00 (+4.71%)
MU   89.39 (-0.68%)
GE   101.31 (+0.69%)
T   27.38 (+0.37%)
F   22.49 (+0.18%)
DIS   151.81 (+1.13%)
AMC   19.12 (+4.37%)
PFE   53.96 (+0.78%)
ACB   5.02 (+3.29%)
BA   220.75 (+1.69%)
QQQ   372.49 (+1.64%)
AAPL   169.11 (+1.73%)
MSFT   310.67 (+2.42%)
FB   324.60 (+1.57%)
GOOGL   2,737.33 (+1.30%)
AMZN   3,132.80 (+0.22%)
TSLA   1,033.83 (+3.83%)
NVDA   253.31 (+1.05%)
BABA   133.69 (+4.66%)
NIO   30.51 (+6.57%)
AMD   127.32 (-0.74%)
CGC   8.00 (+4.71%)
MU   89.39 (-0.68%)
GE   101.31 (+0.69%)
T   27.38 (+0.37%)
F   22.49 (+0.18%)
DIS   151.81 (+1.13%)
AMC   19.12 (+4.37%)
PFE   53.96 (+0.78%)
ACB   5.02 (+3.29%)
BA   220.75 (+1.69%)
QQQ   372.49 (+1.64%)
AAPL   169.11 (+1.73%)
MSFT   310.67 (+2.42%)
FB   324.60 (+1.57%)
GOOGL   2,737.33 (+1.30%)
AMZN   3,132.80 (+0.22%)
TSLA   1,033.83 (+3.83%)
NVDA   253.31 (+1.05%)
BABA   133.69 (+4.66%)
NIO   30.51 (+6.57%)
AMD   127.32 (-0.74%)
CGC   8.00 (+4.71%)
MU   89.39 (-0.68%)
GE   101.31 (+0.69%)
T   27.38 (+0.37%)
F   22.49 (+0.18%)
DIS   151.81 (+1.13%)
AMC   19.12 (+4.37%)
PFE   53.96 (+0.78%)
ACB   5.02 (+3.29%)
BA   220.75 (+1.69%)
NASDAQ:RDUS

Radius Health Stock Forecast, Price & News

$6.87
+0.49 (+7.68%)
(As of 01/20/2022 11:53 AM ET)
Add
Compare
Today's Range
$6.37
$6.88
50-Day Range
$6.11
$18.83
52-Week Range
$5.92
$26.16
Volume
17,631 shs
Average Volume
1.34 million shs
Market Capitalization
$325.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.08
30 days | 90 days | 365 days | Advanced Chart
Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.


Radius Health logo

About Radius Health

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
Employees
310
Year Founded
N/A

Sales & Book Value

Annual Sales
$238.65 million
Book Value
($2.66) per share

Profitability

Net Income
$-109.21 million
Pretax Margin
-33.37%

Debt

Price-To-Earnings

Miscellaneous

Free Float
46,523,000
Market Cap
$325.24 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/20/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

459th out of 1,415 stocks

Pharmaceutical Preparations Industry

214th out of 682 stocks

Analyst Opinion: 3.8Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health
or view top-rated stocks.

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have decreased by 57.3% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Radius Health?

Radius Health saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 7,770,000 shares, an increase of 17.7% from the December 15th total of 6,600,000 shares. Based on an average trading volume of 2,045,100 shares, the short-interest ratio is presently 3.8 days.
View Radius Health's Short Interest
.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Radius Health
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to the consensus estimate of $61.40 million. During the same quarter in the prior year, the firm earned ($0.14) EPS.
View Radius Health's earnings history
.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210 million-$220 million, compared to the consensus revenue estimate of $242.26 million.

What price target have analysts set for RDUS?

5 Wall Street analysts have issued 1 year price objectives for Radius Health's stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Radius Health's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price.
View analysts' price targets for Radius Health
or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • George Kelly Martin, President, Chief Executive Officer & Director
  • Steven Helwig, CFO, Treasurer & Chief Accounting Officer
  • Bruce Mitlak, Chief Medical Officer
  • Averi Price, Secretary, Chief Compliance Officer & VP
  • Chhaya Shah, Chief Business Officer & Senior Vice President

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Radius Health stock include James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends for Radius Health
.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $6.86.

How much money does Radius Health make?

Radius Health has a market capitalization of $324.77 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109.21 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 310 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

Where are Radius Health's headquarters?

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.